Prevention of Recurrent Venous Thrombosis: Warfarin versus Heparin

William M. Miller, Clinton A. Medbery, Daniel L. Clarke-Pearson, Alan F. Barker, Russell Hull, Terry Delmore, Edward Genton, Jack Hirsh, Michael Gent, David Sackett, Dermot Mcloughlin, Peter Armstrong

Research output: Contribution to journalLetter

1 Scopus citations

Abstract

To the Editor: The article by Hull and his colleagues1 presents some interesting data and raises questions about the conclusions drawn. The ineffectiveness of low-dose heparin in that trial may have been related to the primary treatment regimen and may not mean that such therapy is without merit. This possibility is discussed in the editorial by Wessler and Gitel.2 As they pointed out, continuous infusion of intravenous heparin is associated with a decrease in antithrombin III.3 Since heparin acts as a cofactor and greatly accelerates the rate at which antithrombin III inhibits thrombin,4 it seems logical to assume that the. No extract is available for articles shorter than 400 words.

Original languageEnglish (US)
Pages (from-to)752-753
Number of pages2
JournalNew England Journal of Medicine
Volume302
Issue number13
DOIs
StatePublished - Mar 27 1980

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Miller, W. M., Medbery, C. A., Clarke-Pearson, D. L., Barker, A. F., Hull, R., Delmore, T., Genton, E., Hirsh, J., Gent, M., Sackett, D., Mcloughlin, D., & Armstrong, P. (1980). Prevention of Recurrent Venous Thrombosis: Warfarin versus Heparin. New England Journal of Medicine, 302(13), 752-753. https://doi.org/10.1056/NEJM198003273021316